Literature DB >> 14639745

Synthesis, biological activity, and docking studies of new acetylcholinesterase inhibitors of the bispyridinium type.

Petra Kapková1, Nikolaus Stiefl, Ulf Sürig, Bernd Engels, Knut Baumann, Ulrike Holzgrabe.   

Abstract

A novel series of acetylcholinesterase (AChE) inhibitors of the bispyridinium type was synthesized and the inhibitory activity against AChE and butyrylcholinesterase (BChE) measured. In essence, the substitution pattern influenced the inhibitory potency against AChE, where the most active bispyridiniumoxime (TMB-4) was bisbenzyl substituted followed by monobenzyl substituted, bismethyl substituted, and unsubstituted derivatives of TMB-4. Hence, the bisbenzyl ether of TMB-4 was further investigated. In order to obtain diverse lipophilic and electronic properties for these bisbenzyl bispyridinium derivatives (so-called DUO series), the lateral ring substitution was systematically varied. The lowest IC(50) value against AChE found thus far in the DUO series was 0.34 microM. Docking studies were carried out to elucidate the differences in biological activity. A general binding mode for nearly all compounds could be identified by these investigations. In this binding mode, the docked ligands span the narrow, deeply buried active-site gorge, interacting with Trp84 at the bottom of the gorge, Tyr334 or Phe331 halfway down the gorge, and Trp279 at the peripheral anionic site at the mouth of the gorge. For specific ligands, additional interactions were found which helped to explain their deviating activity. Based on the promising characteristics of the novel acetylcholinesterase inhibitors presented, a series of structurally related, optimized candidates will be developed.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14639745     DOI: 10.1002/ardp.200300795

Source DB:  PubMed          Journal:  Arch Pharm (Weinheim)        ISSN: 0365-6233            Impact factor:   3.751


  6 in total

1.  Peripheral site acetylcholinesterase inhibitors targeting both inflammation and cholinergic dysfunction.

Authors:  Sherri Young; Karine Fabio; Christophe Guillon; Pramod Mohanta; Timothy A Halton; Diane E Heck; Robert A Flowers; Jeffrey D Laskin; Ned D Heindel
Journal:  Bioorg Med Chem Lett       Date:  2010-03-03       Impact factor: 2.823

Review 2.  Hybrids: a new paradigm to treat Alzheimer's disease.

Authors:  Manjinder Singh; Maninder Kaur; Navriti Chadha; Om Silakari
Journal:  Mol Divers       Date:  2015-09-02       Impact factor: 2.943

3.  Reactivation of sarin-inhibited pig brain acetylcholinesterase using oxime antidotes.

Authors:  Kamil Kuca; Daniel Jun
Journal:  J Med Toxicol       Date:  2006-12

4.  Synthesis and molecular docking studies of some 4-phthalimidobenzenesulfonamide derivatives as acetylcholinesterase and butyrylcholinesterase inhibitors.

Authors:  Zeynep Soyer; Sirin Uysal; Sulunay Parlar; Ayse Hande Tarikogullari Dogan; Vildan Alptuzun
Journal:  J Enzyme Inhib Med Chem       Date:  2016-10-21       Impact factor: 5.051

Review 5.  Molecular docking studies of coumarin hybrids as potential acetylcholinesterase, butyrylcholinesterase, monoamine oxidase A/B and β-amyloid inhibitors for Alzheimer's disease.

Authors:  Samina Khan Yusufzai; Mohammad Shaheen Khan; Othman Sulaiman; Hasnah Osman; Dalily Nabilah Lamjin
Journal:  Chem Cent J       Date:  2018-12-04       Impact factor: 4.215

6.  Acetylshikonin, a Novel AChE Inhibitor, Inhibits Apoptosis via Upregulation of Heme Oxygenase-1 Expression in SH-SY5Y Cells.

Authors:  Yan Wang; Wen-Liang Pan; Wei-Cheng Liang; Wai-Kit Law; Denis Tsz-Ming Ip; Tzi-Bun Ng; Mary Miu-Yee Waye; David Chi-Cheong Wan
Journal:  Evid Based Complement Alternat Med       Date:  2013-11-05       Impact factor: 2.629

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.